Chemoradiation of locally advanced biliary cancer: A PRISMA-compliant systematic review.

ABSTRACT:

Introduction

Biliary tract cancers (BTC) are rare and aggressive neoplasms. The current management of locally advanced or unresectable BTC is primarily based on chemotherapy (CHT) alone, linked to a median overall survival (OS) of approximately 12 months. However, international guidelines still consider concurrent chemoradiation (CRT) as an alternative treatment option. This study aims to review the current evidence on "modern" CRT for primary or recurrent unresectable BTC.

Materials and methods

A comprehensive search was conducted on PubMed, Scopus, and Cochrane Library to identify relevant papers. Prospective or retrospective trials reporting outcomes after concurrent CRT of unresectable non-metastatic, primary, or recurrent BTC were included. Only English-written papers p

SUBMITTER: Bisello S 

PROVIDER: S-EPMC11632119 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature